- Review
- Open Access
Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials
https://doi.org/10.1186/s13018-018-0871-5
© The Author(s). 2018
- Received: 8 January 2018
- Accepted: 25 June 2018
- Published: 6 July 2018
Abstract
Objective
To assess the symptomatic effectiveness and safety of oral symptomatic slow-acting drugs (SYSADOAs) on the treatment of knee and/or hip osteoarthritis, such as chondroitin, glucosamine, and combination treatment with chondroitin plus glucosamine.
Methods
We searched electronic database including PubMed, Embase, Cochrane Library, and the reference lists of relevant articles published from inception to May 22, 2018. An updated meta-analysis was performed to assess the effectiveness of these slow-acting drugs for osteoarthritis.
Results
Twenty-six articles describing 30 trials met our inclusion criteria and were included in the meta-analysis. The estimates between chondroitin and placebo showed that chondroitin could alleviate pain symptoms and improve function. Compared with placebo, glucosamine proved significant effect only on stiffness improvement. However, the combination therapy did not have enough evidence to be superior to placebo. Additionally, there was no significant difference in the incidence of AEs and discontinuations of AEs when compared with placebo.
Conclusions
Given the effectiveness of these symptomatic slow-acting drugs, oral chondroitin is more effective than placebo on relieving pain and improving physical function. Glucosamine showed effect on stiffness outcome. Regarding on the limited number of combination therapy, further studies need to investigate the accurate effectiveness. This information accompanied with the tolerability and economic costs of included treatments would be conducive to making decisions for clinicians.
Keywords
- Osteoarthritis
- Glucosamine
- Chondroitin
- Treatment
Background
Osteoarthritis (OA), characterized by progressive cartilage matrix degradation, subchondral bone sclerosis, and osteophyte formation, is the most common form of arthritis [1, 2]. Globally, the prevalence of OA, particularly of the large weight-bearing joints such as the knee and hip, is also predicted to grow [3]. Presently, OA has emerged as one of the major public health concerns and continues to affect about 10% of men and 18% of women over 60 years of age [1].
Previous studies suggest that aging, genetic predisposition, obesity, inflammation, and excessive mechanical loading predispose to OA occurrence and development [4]. The structural changes result in joint pain and stiffness, swelling, and tenderness, which can eventually lead to disability and affect the quality of life of patients [5]. Treatment strategies of OA include both non-pharmacological and pharmacological therapies. Among pharmacological therapies, analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) are current treatment options for OA because of their well-established effectiveness. However, they act as symptomatic treatments without offering disease modification of OA, and they are accused for increased risk adverse events, including the gastrointestinal and/or cardiovascular system [6]. For this reason, attention has recently been focused on an ideal treatment, which can improve the clinical symptoms of OA with better tolerability and safety profiles, such as symptomatic slow-acting drugs (SYSADOAs) [7].
Glucosamine and chondroitin, as important medicine in those SYSADOA, are naturally occurring compounds in the body functioning as the principal substrates in the biosynthesis of proteoglycan [8, 9]. It is suggested that glucosamine and chondroitin are both partially absorbed and then reaches the joints, exerting on relieving joint pain and slowing the rate of joint destruction and cartilage loss. They are two main categories of agents potentially or theoretically acting as chondroprotective agents and disease-modifying OA drugs (DMOADs) [8, 10]. The effectiveness based on the result of RCT published in 2013 suggested that consumption of chondroitin for certain dosage has a positive effect on pain relief and function improvement [7]. Recently, a trial conducted in 2017 demonstrated a lack of superiority of chondroitin and glucosamine combination therapy over placebo [11]. Although many studies have shown a significant treatment effect, accompanied with remarkable safety, there is still controversy regarding the effectiveness of these putative DMOADs compared with placebo [7, 11]. International guidelines for the management of OA had given an equivocal recommendation of glucosamine and chondroitin, and they are not recommended according to Osteoarthritis Research Society International (OARSI) guidelines published in 2014 [12].
Therefore, based on existing evidence, a study needs to be updated and critically evaluates the current evidence-based information about the administration of glucosamine and chondroitin for the treatment of knee or hip OA. In our study, a relatively comprehensive meta-analysis was performed to assess the effectiveness and safety of putative DMOADs.
Methods
Search strategy
We conducted this meta-analysis following the PRISMA extension statement [13]. We systematically searched electronic database including PubMed, Embase, and Cochrane Library based on logic combination of keywords and text words associated with OA to extract concerned RCTs from inception to May 22, 2018. The Internet-based search used the following terms: “arthritis,” “osteoarthritis,” “OA,” “joint disease,” “glucosamine,” “GH,” “GS,” “chondroitin,” “CH,” “CS,” and the corresponding free terms. The search was restricted to English language and studies of human participants. We then screened reference lists of all obtained articles, including relevant reviews, to avoid missing relevant articles. And, we also searched ClinicalTrials.gov for progressive trials.
Inclusion and exclusion criteria
Studies were included if they met the following criteria: (1) RCTs; (2) studies about primary hip and/or knee OA patients with clinical and/or radiologic diagnosis; (3) studies covering at least two of the following oral treatments: glucosamine, chondroitin, or the two in combination against placebo; and (4) extractable data reporting the pain, function, stiffness, and the adverse events (AEs) of patients.
The exclusion criteria were as follows: (1) studies of non-randomized and/or uncontrolled trials, (2) treatment methods described unclearly, (3) interventions combined with non-steroidal anti-inflammatory drugs, (4) studies or data reported repeatedly, and (5) trial arms with sub-therapeutic doses (< 1500 mg/day of glucosamine and < 800 mg/day of chondroitin (according to dosage licensed in Europe)) [14].
Data extraction
Two investigators (X.Y.Z and L.L.S) independently assessed all studies for eligibility and extracted data in accordance with a preconfigured form from each study. Any disagreements were resolved through discussion with a third reviewer (L.Y.J). For each study, patients’ characteristics including mean age, sex, mean duration of symptom, BMI, duration of follow-up, type of outcome (pain, function, stiffness, and AEs), trial design, trial size, details of intervention, treatment duration, and results were individually extracted. Data of intention-to-treat analysis was employed whenever possible.
Quality assessment
The Cochrane Risk of Bias Tool was used to evaluate the methodological quality of the included studies (version 5.3) [15]. The tool evaluated seven potential risks of bias: random sequence generation, allocation concealment, blinding of participants, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. Each item was judged by the following criteria: low risk of bias, uncertain risk of bias, and high risk of bias. Whenever studies included three or more high risk of bias, it was considered as poor methodological quality. Two reviewers (X.Y.Z and L.L.S) checked the profile of each included study independently.
Outcome measures
The primary outcomes of this meta-analysis were pain intensity, function improvement, and stiffness score from baseline to the end of treatment. The secondary outcome was safety of studies. We preferred to the scale that was recognized to be the highest on the hierarchy of those suggested outcomes when more than one pain scales were given for a trial. Among these scales, global pain has precedence over pain on walking and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale [16, 17]. Similarly, the data of function and stiffness was extracted with the same method. If global function score was not reported, the walking disability, function subscale of WOMAC, or Lequesne Index would be applied instead.
The standard mean difference (SMD) was used to calculate the difference between two interventions because different studies assessed the same outcome by employing different scales. SMD expresses the size of the intervention effect in each study relative to the variability observed in that study by dividing the pooled SD of the differences between two interventions [18, 19]. The effect size was transformed back to the different units of the WOMAC Visual Analogue Scale (VAS), the most commonly used scale based on a media pooled SD of 2.5 cm to assess pain on the scale of 0 to 10 cm. A standardized WOMAC function score (0–10) was transformed by SMD, which based on a median pooled SD of 2.1 units. A change of 2 points on the 0–10 scale was interpreted clinically significant improvement [20]. The negative effect size indicated a better treatment effect on pain relief and function improvement.
Statistical analysis
All results summarized using STATA software (version 13.1, StataCorp, College Station, TX). For continuous outcomes, SMD with 95% credible interval (CI) was used to present the effect size. For counting data, we calculated relative risk (RR) with 95% CI. The heterogeneity between studies was tested using the Q statistics. P < 0.1 was considered statistically significant. And, I2 was used to quantify the inconsistency among the potentially disparate sources of studies. A random-effects model was used if I2 > 50%. A subgroup analysis was conducted because there were different types of SYSADOA. Publication bias was examined through visual inspection of funnel plot asymmetry. A sensitivity analysis was performed to evaluate the effect of each study on the combined effect size by omitting each study.
Results
Study selection and characteristics
Characteristics of the included studies for osteoarthritis of knee and/or hip
Study, year | Treatment (daily dose) | Participants randomized (n) | Treatment duration (weeks) | Symptom duration (year) | Mean age (year) | Female (%) | OA grade | Joint | Pain outcome extracted | Timepoint extracted (weeks) |
|---|---|---|---|---|---|---|---|---|---|---|
Glucosamine vs placebo | ||||||||||
Noack 1994 [21] | G(1500 mg)/placebo | 126/126 | 1–4 | 2.00–10.00 | 55.00 | 60 | I–III | Knee | Lequesne global scale | 4 |
Houpt 1999 [22] | G(1500 mg)/placebo | 58/60 | 1–8 | 8.30 | 64.46 | 62 | NA | Knee | WOMAC | 12 |
Reginster 2001 [23] | G(1500 mg)/placebo | 106/106 | 1–144 | 7.80 | 65.75 | 76 | II–III | Knee | WOMAC | 144 |
Pavelka 2002 [24] | G(1500 mg)/placebo | 101/101 | 1–144 | 10.55 | 62.35 | 79 | II–III | Knee | WOMAC | 144 |
Braham 2003 [25] | G(1500 mg)/placebo | 24/22 | 1–12 | 12.98 | 42.65 | 28 | I–III | Knee | KPS | 12 |
McAlinton 2004 [26] | G(1500 mg)/placebo | 101/104 | 1–12 | NA | > 65.00 | 64 | NA | Knee | WOMAC | 12 |
Cibere 2004 [27] | G(1500 mg)/placebo | 71/66 | 1–24 | 1.60 | 64.48 | 56 | ≥ 2 | Knee | WOMAC | 24 |
Usha 2004 [28] | G(1500 mg)/placebo | 30/28 | 1–12 | 3.05 | 51.03 | NA | I–III | Knee | VAS | 12 |
Clegg 2006 [29] | G(1500 mg)/placebo | 317/313 | 1–24 | 9.95 | 58.40 | 63 | II–III | Knee | WOMAC | 24 |
Herrero-Beaumont 2007 [30] | G(1500 mg)/placebo | 106/104 | 1–12 | 7.30 | 63.94 | 93 | II–III | Knee | WOMAC | 24 |
Rozendaal 2008 [31] | G(1500 mg)/placebo | 111/111 | 1–12 | 11.70 | 63.40 | 69 | > 2 | Hip | WOMAC | 96 |
Giordano 2009 [32] | G(1500 mg)/placebo | 30/30 | 1–12 | 6.30 | 57.65 | 70 | I–III | Knee | WOMAC | 24 |
Fransen 2014 [33] | G(1500 mg)/placebo | 152/151 | 1–48 | > 2.00 | 60.90 | 83 | NA | Knee | WOMAC | 96 |
Kwoh 2014 [34] | G(1501 mg)/placebo | 98/103 | 1–12 | NA | 52.23 | 49 | 0–4 | Knee | WOMAC | 24 |
Chondroitin vs Placebo | ||||||||||
Bucsi 1998 [35] | C(1200 mg)/placebo | 39/46 | 1–12 | > 0.50 | 59.95 | 60 | I–III | Knee | VAS | 24 |
Bourgeois 1998 [36] | C(1200 mg)/placebo | 83/44 | 1–13 | NA | 63.35 | 76 | I–III | Knee | VAS | 13 |
Uebelhart 1998 [37] | C(1200 mg)/placebo | 23/23 | 1–48 | NA | 58.50 | 52 | I–III | Knee | VAS | 48 |
Mazieres 2001 [38] | C(1200 mg)/placebo | 63/67 | 1–12 | NA | 67.09 | 75 | II–III | Knee | Pain at rest | 12 |
Uebelhart 2004 [39] | C(1200 mg)/placebo | 54/56 | 1–12 | NA | 63.45 | 81 | I–III | Knee | Husskisson visual analogue score for pain | 12 |
Michel 2005 [40] | C(1200 mg)/placebo | 150/150 | 1–96 | NA | 62.80 | 51 | I–III | Knee | WOMAC | 96 |
Clegg 2006 [29] | C(1200 mg)/placebo | 318/313 | 1–24 | 9.60 | 58.20 | 64 | II–III | Knee | WOMAC | 24 |
Mazieres 2006 [41] | C(1200 mg)/placebo | 153/154 | 1–24 | 6.40 | 66.00 | 70 | II–III | Knee | Pain at rest | 24 |
Kahan 2009 [42] | C(1200 mg)/placebo | 309/313 | 1–12 | 6.30 | 62.30 | 68 | I–III | Knee/hip | WOMAC | 12 |
Wildi 2011 [43] | C(800 mg)/placebo | 35/34 | 1–48 | > 0.50 | 62.26 | 59 | I–III | Knee | WOMAC | 48 |
Zegels 2013 [7] | C(1200 mg)/placebo | 236/117 | 1–12 | NA | 65.17 | 65 | NA | Knee | Global pain | 12 |
Fransen 2014 [33] | C(800 mg)/placebo | 151/151 | 1–48 | > 2.00 | 60.05 | 83 | NA | Knee | WOMAC | 96 |
Glucosamine + Chondroitin vs Placebo | ||||||||||
Clegg 2006 [29] | G + C(1500 + 1200 mg)/placebo | 317/313 | 1–24 | 9.80 | 58.40 | 63 | II–III | Knee | WOMAC | 24 |
Fransen 2014 [33] | G + C(1500 + 800 mg)/placebo | 151/151 | 1–48 | > 2.00 | 60.65 | 85 | NA | Knee | WOMAC | 96 |
Lugo 2016 [44] | G + C(1500 + 1200 mg)/placebo | 65/58 | 1–12 | NA | 52.84 | 54 | II–III | Knee | WOMAC | 24 |
Roman-Blas 2017 [11] | G + C(1500 + 1200 mg)/placebo | 80/78 | 1–24 | 6.20 | 65.99 | 84 | II–III | Knee | Global pain | 24 |
Risk of bias
Risk of bias in those included studies was summarized in Additional file 1: Figure S2. All studies were judged as low risk of bias for blinding to patients. Randomization was mentioned in all trails. Nevertheless, 6% did not report details of adequate sequence generation. All studies were judged as low risk of bias for blinding for patients, while 65% for blinding to outcome assessment. In addition, 15% trails did not describe the method of allocation concealment and 92% reported complete outcome data. None of the studies was thought to have poor methodological quality.
Pain
All studies (7127 patients) contributed to the meta-analysis of pain-related outcomes for the putative DMOADs compared with placebo (Table 1). Fourteen trials (2845 randomized patients) compared glucosamine with placebo [21–34]. Twelve trials (3082 randomized patients) compared chondroitin with placebo [7, 29, 33, 35–43]. Four trials (1200 randomized patients) compared the two in combination with placebo [11, 29, 33, 44].
Effect sizes of symptomatic outcomes
Outcomes | Interventions | No. of studies | Test of association | Test of heterogeneity | ||||
|---|---|---|---|---|---|---|---|---|
SMD | 95% CI | P value | Model | I2 (%) | P value | |||
Pain | G vs. PBO | 14 | − 0.105 | (− 0.254, 0.045) | 0.170 | Random | 72.50 | 0.000 |
C vs. PBO | 12 | − 0.216 | (− 0.360, − 0.071) | 0.003 | Random | 70.80 | 0.000 | |
G + C vs. PBO | 4 | 0.792 | (− 0.296, 1.880) | 0.153 | Random | 98.50 | 0.000 | |
Overall | 30 | − 0.071 | (− 0.228, 0.085) | 0.369 | Random | 90.10 | 0.000 | |
Function | G vs. PBO | 11 | − 0.126 | (− 0.264, 0.012) | 0.073 | Random | 64.10 | 0.002 |
C vs. PBO | 10 | − 0.220 | (− 0.358, − 0.081) | 0.002 | Random | 68.30 | 0.001 | |
G + C vs. PBO | 4 | 0.556 | (− 0.368, 1.480) | 0.238 | Random | 98.00 | 0.000 | |
Overall | 25 | − 0.090 | (− 0.242, 0.061) | 0.242 | Random | 89.00 | 0.000 | |
Stiffness | G vs. PBO | 8 | − 0.305 | (− 0.609, − 0.002) | 0.048 | Random | 89.00 | 0.000 |
C vs. PBO | 3 | 0.026 | (− 0.073, 0.126) | 0.604 | Fixed | 31.70 | 0.232 | |
G + C vs. PBO | 2 | − 0.070 | (− 0.214, 0.074) | 0.340 | Fixed | 0.00 | 0.582 | |
Overall | 13 | − 0.142 | (− 0.301, 0.017) | 0.081 | Random | 82.90 | 0.000 | |
Function
Twenty-five trials (6667 patients) contributed to the meta-analysis of physical function. Table 2 showed estimates across different treatments compared with placebo. In general, the summary of DMOADs had a better effect compared with placebo. The overall effect size was − 0.090 (95% CI, − 0.242 to 0.061). After being transformed, the effect size for the subgroup of chondroitin versus placebo was − 0.462 units (95% CI, − 0.752 to − 0.170 units). Meanwhile, other comparisons presented no significant effect.
Stiffness
Thirteen trials (4079 patients) contributed to the outcome of stiffness. The overall difference in stiffness improvement versus placebo was − 0.142 (95% CI, − 0.301 to 0.017) for the summary of these treatments, − 0.305 (95% CI, − 0.609 to 0.002) for glucosamine, 0.026 (95% CI, − 0.073 to 0.126) for chondroitin and − 0.070 (95% CI, − 0.214 to 0.074) for the combination of glucosamine and chondroitin (Table 2). In terms of stiffness, only glucosamine showed statistical significance when compared with placebo.
Safety
Forest plot of RR and 95% CIs of studies of adverse events. RR relative risk, 95% CI confidence interval, G + C glucosamine + chondroitin
Risk ratio (95% CI) of specific adverse effects between different treatment groups
Comparison | GI AE | CV AE | CNS AE | MU AE | Infection | Skin AE | Others |
|---|---|---|---|---|---|---|---|
G vs PBO | 0.99(0.79, 1.23) | NA | 0.72(0.46, 1.10) | 1.52(0.88, 2.63) | 1.07(0.50, 2.32) | 0.80(0.38, 1.68) | 1.21(0.98, 1.48) |
C vs PBO | 0.35(0.14, 0.87) | 1.13(0.45, 2.84) | 0.79(0.37, 1.67) | NA | 0.98(0.72, 1.34) | 1.00(0.41, 2.45) | NA |
G + C vs PBO | 2.79(0.30, 26.00) | NA | 1.86(0.36, 9.74) | 2.79(0.30, 26.00) | 2.79(0.12, 67.10) | NA | 4.66(0.23, 94.79) |
Overall | 0.92(0.74, 1.13) | 1.13(0.45, 2.84) | 0.77(0.54, 1.11) | 1.58(0.93, 2.70) | 1.01(0.76, 1.35) | 0.88(0.50, 1.55) | 1.22(1.00, 1.50) |
Sensitivity analysis
We also conducted sensitivity analyses for those outcomes to confirm the robustness of the results. Sensitivity analysis of sample size and methodological quality of included studies did not show any major change in view of pain, function, and stiffness (Additional file 1: Table S1).
Discussion
In this study, we performed four individual outcome-oriented meta-analyses of randomized control trials selected on the basis of their high methodologic quality, assessing the effectiveness and safety of glucosamine, chondroitin, and the combination for the treatment of knee and/or hip OA. In our meta-analysis, the pooled effect sizes suggested that these SYSADOAs showed no significant effect on the outcome of pain, function, and stiffness compared with placebo. However, the estimates between chondroitin and placebo showed that chondroitin could alleviate pain symptoms and improve function. Compared with placebo, glucosamine proved significant effect only on the sapect of stiffness improvement. Whereas, in this head-to-head meta-analysis, the combination of glucosamine and chondroitin did not have enough evidence to be superior to placebo. There was no significant difference in the incidence of AEs and discontinuations of AEs for these SYSADOAs when compared with placebo.
Glucosamine and chondroitin are dietary supplements commonly used by those OA patents and are recommended by physician for purported analgesic and chondroprotective effects [45]. Glucosamine was considered as a water-soluble amino monosaccharide, which was one of the most abundant monosaccharides in the human body and is in high quantities in articular cartilage. Chondroitin was a major component of the extracellular matrix of articular cartilage, which played an important role in creating considerable osmotic pressure. In this way, it could provide cartilage with resistance and elasticity to resist tensile stresses during loading condition [46]. Chondroitin and glucosamine were tested in several clinical trials of osteoarthritis. In spite of the controversy surrounding the SYSADOAs, they were commonly used to control symptoms of OA in western countries. Therefore, an understanding of chondroitin and glucosamine consumption is of significance for public health.
In the previous meta-analysis, Richy and colleagues combined 7 trials of glucosamine and 8 trials of chondroitin for osteoarthritis treatment demonstrated comparable efficacies of chondroitin and glucosamine and a highly significant effectiveness of glucosamine on all involved outcomes when compared with placebo, which was contrary with our results of glucosamine and the combination therapy [47]. Collectively, their study showed that chondroitin was considered effective on pain relief, which was consistent with our finding. Additionally, a pair-wise meta-analysis of chondroitin by Monfort and colleagues suggested that chondroitin present a slight to moderate efficacy in the symptomatic treatment of OA, with an excellent safety profile [48]. The subgroup of our study covering 12 RCTs of chondroitin present that chondroitin showed significant effect in both outcome of pain and function improvement. In our study, only 4 RCTs met the criteria of combination therapy and were included in the subgroup of this meta-analysis. And glucosamine and chondroitin combination therapy failed to reduce joint pain and function improvement; this may due to original data restraints. However, this finding was similar to a least RCT publish in 2017. Roman-Blas and his colleagues indicated that chondroitin and glucosamine combination therapy failed to reduce joint pain [11]. But in the subgroup of patients with moderate-to-severe knee pain of their RCT, significant relief of joint pain with this combination therapy was observed.
Considering the reasons above, we do not oppose the use of chondroitin, although chondroitin were not recommended according to Osteoarthritis Research Society International (OARSI) guidelines published in 2014. In fact, we recommend that the future guidelines would reconsider the oral treatment option of chondroitin for the treatment of OA in the clinical feature. In terms of the aspect of safety, the current study provides valuable information to help physicians make treatment decisions for OA patients.
It was worth mentioning that a comprehensive and rigorous literature search strategy was performed in our meta-analysis, which insured that it was unlikely to miss other relevant trials. All the methods were strict inclusion and exclusion criteria to demonstrate the effectiveness and significance of our conclusions. In our meta-analysis, dosage was strictly restricted and the RCTs included should met these criteria, so the results could be comparable and reasonable. To minimize bias, studies selection, quality assessment, and data extraction were completed by two reviewers independently. What is more, several sensitivity analyses of low quality were conducted to make the results more sensible and comprehensive.
There are several limitations in this meta-analysis that need to be considered. Firstly, the quality of original data resulted in some limitation of the quality of our analysis. Secondly, in this study, there is potential publication bias. Some unpublished papers and abstracts were not taken into consideration because of unavailable data. The language might also introduce a bias. Actually, we selected only the English language. Thirdly, several specific adverse effects of interventions cannot be proven due to the inadequate reporting of adverse event data. Moreover, the numbers of RCTs between combination therapy of glucosamine and chondroitin were limited. Researches on SYSADOAs are still required due to the limitations on the quality and quantity of the available evidence.
Conclusion
In conclusion, in accordance with our results, it can be definitively stated that oral chondroitin in recommended dosage is more effective than placebo on relieving pain and improving physical function. Compared with placebo, glucosamine showed significant effect on the outcome of stiffness. In the aspect of safety, both compounds are well tolerated. Actually, combination therapy is definitely common in clinical practice, and treatment intervention on OA patients like the combination of SYSADOAs was also usual in clinical experience. Our study would help highlight the potential role of SYSADOAs. Further studies of the glucosamine and chondroitin combination therapy need to explore the effectiveness for an accurate characterization of osteoarthritis treatment and their possible mechanism. Therefore, the above information, along with the safety profile should be conducive to clinicians in decision making.
Abbreviations
- AEs:
-
Adverse effects
- DMOADs:
-
Disease-modifying OA drugs
- NSAIDs:
-
Non-steroidal anti-inflammatory drugs
- OA:
-
Osteoarthritis
- OARSI:
-
Osteoarthritis Research Society International
- RR:
-
Relative risk
- SYSADOAs:
-
Symptomatic slow-acting drugs
Declarations
Funding
This study was supported by the Research Innovation Program for College Graduates of Jiangsu Province (YKC16019) and Jiangsu Students’ Platform for Innovation and Entrepreneurship Training Program (201710304058).
Authors’ contributions
All authors certified that they have participated in the conceptual design of this work, the analysis of the data, and the writing of the manuscript to take public responsibility for it. XZ drafted the protocol and wrote the final paper. LJ contributed to the research design and made critical revisions. LS and DW participated in data collection. JR participated in the data analysis. All authors reviewed the final version of the manuscript and approve it for publication.
Ethics approval and consent to participate
Not applicable
Consent for publication
Written informed consent was obtained from all patients for data publication, including images.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Authors’ Affiliations
References
- Glyn-Jones S, Palmer AJ, Agricola R, et al. Osteoarthritis. Lancet. 2015;386(9991):376–87.View ArticlePubMedGoogle Scholar
- Lotz M, Martel-Pelletier J, Christiansen C, et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis. 2013;72(11):1756–63.View ArticlePubMedPubMed CentralGoogle Scholar
- Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 1998;41(8):1343–55.View ArticlePubMedGoogle Scholar
- arc OC, arc OC, Zeggini E, et al. Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association study. Lancet. 2012;380(9844):815–23.View ArticleGoogle Scholar
- Nuesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Juni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. Bmj. 2011;342:d1165.View ArticlePubMedPubMed CentralGoogle Scholar
- Essex MN, O'Connell MA, Behar R, Bao W. Efficacy and safety of nonsteroidal anti-inflammatory drugs in Asian patients with knee osteoarthritis: summary of a randomized, placebo-controlled study. Int J Rheum Dis. 2016;19(3):262–70.View ArticlePubMedGoogle Scholar
- Zegels B, Crozes P, Uebelhart D, Bruyere O, Reginster JY. Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthr Cartil. 2013;21(1):22–7.View ArticlePubMedGoogle Scholar
- Persiani S, Rotini R, Trisolino G, et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthr Cartil. 2007;15(7):764–72.View ArticlePubMedGoogle Scholar
- Conte A, Volpi N, Palmieri L, Bahous I, Ronca G. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittelforschung. 1995;45(8):918–25.PubMedGoogle Scholar
- Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthr Cartil. 1998;6 Suppl A:37–8.View ArticlePubMedGoogle Scholar
- Roman-Blas JA, Castañeda S, Sánchez-Pernaute O, Largo R, Herrero-Beaumont G. Combined treatment with chondroitin sulfate and glucosamine sulfate shows no superiority over placebo for reduction of joint pain and functional impairment in patients with knee osteoarthritis: a six-month multicenter, randomized, double-blind, Placebo-Controlled Clinical Trial. Arthritis Rheumatol. 2017;69(1):77–85.Google Scholar
- McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartil. 2014;22(3):363–88.View ArticlePubMedGoogle Scholar
- Panic N, Leoncini E, Belvis G D, et al. Evaluation of the endorsement of the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) statement on the quality of published systematic review and meta-analyses[J]. Plos One. 2013;8(12):e83138.Google Scholar
- European Medicines Agency. EMEA public statement on the suspension of the marketing authorisation for Bextra (valdecoxib) in the European Union [online]. (2005) Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/12/WC500018391.pdf.
- Green JPTHaS. Corchrane Reviewers’ Handbook 5.1.0. Review Manage 2011.Google Scholar
- Juni P, Reichenbach S, Dieppe P. Osteoarthritis: rational approach to treating the individual. Best Pract Res Clin Rheumatol. 2006;20(4):721–40.View ArticlePubMedGoogle Scholar
- Juhl C, Lund H, Roos EM, Zhang W, Christensen R. A hierarchy of patient-reported outcomes for meta-analysis of knee osteoarthritis trials: empirical evidence from a survey of high impact journals. Arthritis. 2012;2012:136245.View ArticlePubMedPubMed CentralGoogle Scholar
- Cooper HM, Hedges LV. The handbook of research synthesis. New York: Russell Sage Foundation; 1994.Google Scholar
- Cooper HM, Hedges LV, Valentine JC. The handbook of research synthesis and meta-analysis. 2nd ed. New York: Russell Sage Foundation; 2009.Google Scholar
- Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46–54.View ArticlePubMedGoogle Scholar
- Noack W, Fischer M, Forster KK, Rovati LC, Setnikar I. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthr Cartil. 1994;2(1):51–9.View ArticlePubMedGoogle Scholar
- Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol. 1999;26(11):2423–30.PubMedGoogle Scholar
- Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251–6.View ArticlePubMedGoogle Scholar
- Pavelká K, Gatterová J, Olejarová M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162(18):2113–23.View ArticlePubMedGoogle Scholar
- Braham R, Dawson B, Goodman C. The effect of glucosamine supplementation on people experiencing regular knee pain. Br J Sports Med. 2003;37(1):45.View ArticlePubMedPubMed CentralGoogle Scholar
- McAlindon T, Formica M, LaValley M, Lehmer M, Kabbara K. Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trial. Am J Med. 2004;117(9):643–9.View ArticlePubMedGoogle Scholar
- Cibere J, Kopec JA, Thorne A, et al. Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum. 2004;51(5):738–45.View ArticlePubMedGoogle Scholar
- Usha PR, Naidu MU. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Investig. 2004;24(6):353–63.View ArticlePubMedGoogle Scholar
- Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795–808.View ArticlePubMedGoogle Scholar
- Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007;56(2):555–67.View ArticlePubMedGoogle Scholar
- Rozendaal RM, Koes BW, van Osch GJ, et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med. 2008;148(4):268–77.View ArticlePubMedGoogle Scholar
- Giordano N, Fioravanti A, Papakostas P, Montella A, Giorgi G, Nuti R. The efficacy and tolerability of glucosamine sulfate in the treatment of knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Curr Ther Res. 2009;70(3):185–96.View ArticlePubMedGoogle Scholar
- Fransen M, Agaliotis M, Nairn L, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015;74(5):851–8.View ArticlePubMedGoogle Scholar
- Kwoh CK, Roemer FW, Hannon MJ, et al. Effect of oral glucosamine on joint structure in individuals with chronic knee pain: a randomized, placebo-controlled clinical trial. Arthritis Rheum. 2014;66(4):930–9.View ArticleGoogle Scholar
- Bucsi L, Poór G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthr Cartil. 1998;6 Suppl A(5):31–6.View ArticlePubMedGoogle Scholar
- Bourgeois P, Chales G, Dehais J, Delcambre B, Kuntz JL, Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo. Osteoarthr Cartil. 1998;6(Suppl A):25–30.View ArticlePubMedGoogle Scholar
- Uebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthr Cartil. 1998;6 Suppl A(21):39–46.View ArticlePubMedGoogle Scholar
- Mazieres B, Combe B, Van AP, Tondut J, Grynfeltt M. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. J Rheumatol. 2001;28(1):173–81.PubMedGoogle Scholar
- Uebelhart D, Malaise M, Marcolongo R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthr Cartil. 2004;12(4):269–76.View ArticlePubMedGoogle Scholar
- Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 2005;52(3):779–86.View ArticlePubMedGoogle Scholar
- Mazieres B, Hucher M, Zaim M, Garnero P. Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2007;66(5):639–45.View ArticlePubMedPubMed CentralGoogle Scholar
- Kahan A, Uebelhart D, De VF, Delmas PD, Reginster JY. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60(2):524–33.View ArticlePubMedGoogle Scholar
- Wildi LM, Raynauld JP, Martelpelletier J, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis. 2011;70(6):982–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutr J. 2016;15:14.View ArticlePubMedPubMed CentralGoogle Scholar
- DiNubile NA. Glucosamine and chondroitin sulfate in the management of osteoarthritis. Commentary Postgrad Med 2009;121(4):48–50.Google Scholar
- Jomphe C, Gabriac M, Hale TM, et al. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-kappaB in interleukin-1beta-stimulated chondrocytes. Basic Clin Pharmacol Toxicol. 2008;102(1):59–65.PubMedGoogle Scholar
- Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med. 2003;163(13):1514–22.View ArticlePubMedGoogle Scholar
- Monfort J, Martel-Pelletier J, Pelletier J-P. Chondroitin sulphate for symptomatic osteoarthritis: critical appraisal of meta-analyses. Curr Med Res Opin. 2008;24(5):1303–8.View ArticlePubMedGoogle Scholar
